Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Etalanetug by Eisai for Dementia: Likelihood of Approval
Etalanetug is under clinical development by Eisai and currently in Phase III for Dementia. According to GlobalData, Phase III drugs...
Risk adjusted net present value: What is the current valuation of Eisai's Etalanetug?
Etalanetug is a monoclonal antibody commercialized by Eisai, with a leading Phase III program in Dementia. According to Globaldata, it...
Etalanetug by Eisai for Alzheimer's Disease: Likelihood of Approval
Etalanetug is under clinical development by Eisai and currently in Phase III for Alzheimer's Disease. According to GlobalData, Phase III...